SEC Form 25-NSE filed by Ventyx Biosciences Inc.

3/4/26 9:37:54 AM ET

$VTYX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $VTYX alert in real time by email

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

UNITED STATES

OMB APPROVAL

OMB Number:		3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:		1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-40928

Issuer:	Ventyx Biosciences, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	12790 El Camino Real
	Suite 222
	San Deigo	CALIFORNIA	92130
Telephone number:				760-407-6511

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-03-04	By	Jennifer Fainer		CDO Analyst
Date		Name		Title

¹	Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $VTYX alert in real time by email

Recent Analyst Ratings for

$VTYX

Date	Price Target	Rating	Analyst
11/5/2025	$18.00	Neutral → Buy	H.C. Wainwright
3/12/2024	$12.00	Perform → Outperform	Oppenheimer
3/12/2024	$7.00 → $16.00	Equal Weight → Overweight	Wells Fargo
11/7/2023	$46.00 → $6.00	Overweight → Equal-Weight	Morgan Stanley
11/7/2023		Outperform → Perform	Oppenheimer
11/7/2023		Buy → Neutral	H.C. Wainwright
11/7/2023	$6.00	Buy → Hold	Stifel
11/7/2023	$77.00 → $8.00	Overweight → Equal Weight	Wells Fargo

More analyst ratings

SEC Form 25-NSE filed by Ventyx Biosciences Inc.

3/4/26 9:37:54 AM ET

$VTYX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $VTYX alert in real time by email

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

UNITED STATES

OMB APPROVAL

OMB Number:		3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:		1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-40928

Issuer:	Ventyx Biosciences, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	12790 El Camino Real
	Suite 222
	San Deigo	CALIFORNIA	92130
Telephone number:				760-407-6511

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

2026-03-04	By	Jennifer Fainer		CDO Analyst
Date		Name		Title

¹	Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $VTYX alert in real time by email

Recent Analyst Ratings for

$VTYX

Date	Price Target	Rating	Analyst
11/5/2025	$18.00	Neutral → Buy	H.C. Wainwright
3/12/2024	$12.00	Perform → Outperform	Oppenheimer
3/12/2024	$7.00 → $16.00	Equal Weight → Overweight	Wells Fargo
11/7/2023	$46.00 → $6.00	Overweight → Equal-Weight	Morgan Stanley
11/7/2023		Outperform → Perform	Oppenheimer
11/7/2023		Buy → Neutral	H.C. Wainwright
11/7/2023	$6.00	Buy → Hold	Stifel
11/7/2023	$77.00 → $8.00	Overweight → Equal Weight	Wells Fargo

More analyst ratings

SEC Form 25-NSE filed by Ventyx Biosciences Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$VTYX

SEC Form 25-NSE filed by Ventyx Biosciences Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$VTYX

$VTYX
Analyst Ratings

Ventyx Biosciences upgraded by H.C. Wainwright with a new price target

Ventyx Biosciences upgraded by Oppenheimer with a new price target

Ventyx Biosciences upgraded by Wells Fargo with a new price target

$VTYX
Press Releases

Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases

Ventyx Provides Clinical and Corporate Updates

Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare Conference

$VTYX
Insider Trading

Senior VP, Finance Gonzales Roy returned 5,313 shares to the company, closing all direct ownership in the company (SEC Form 4)

Director Subramaniam Somu returned 3,337,495 shares to the company (SEC Form 4)

SEC Form 4 filed by Director White William Richard

$VTYX
SEC Filings

SEC Form S-8 POS filed by Ventyx Biosciences Inc.

SEC Form S-8 POS filed by Ventyx Biosciences Inc.

SEC Form S-8 POS filed by Ventyx Biosciences Inc.

$VTYX
Insider Purchases

Director Gujrathi Sheila bought $300,573 worth of shares (130,000 units at $2.31) (SEC Form 4)

CEO AND PRESIDENT Mohan Raju bought $959,889 worth of shares (500,000 units at $1.92), increasing direct ownership by 30% to 2,175,028 units (SEC Form 4)

$VTYX
Leadership Updates

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

$VTYX
Financials

Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

$VTYX
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

SEC Form 25-NSE filed by Ventyx Biosciences Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $VTYX

SEC Form 25-NSE filed by Ventyx Biosciences Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $VTYX

$VTYX Analyst Ratings

Ventyx Biosciences upgraded by H.C. Wainwright with a new price target

Ventyx Biosciences upgraded by Oppenheimer with a new price target

Ventyx Biosciences upgraded by Wells Fargo with a new price target

$VTYX Press Releases

Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases

Ventyx Provides Clinical and Corporate Updates

Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare Conference

$VTYX Insider Trading

Senior VP, Finance Gonzales Roy returned 5,313 shares to the company, closing all direct ownership in the company (SEC Form 4)

Director Subramaniam Somu returned 3,337,495 shares to the company (SEC Form 4)

SEC Form 4 filed by Director White William Richard

$VTYX SEC Filings

SEC Form S-8 POS filed by Ventyx Biosciences Inc.

SEC Form S-8 POS filed by Ventyx Biosciences Inc.

SEC Form S-8 POS filed by Ventyx Biosciences Inc.

$VTYX Insider Purchases

Director Gujrathi Sheila bought $300,573 worth of shares (130,000 units at $2.31) (SEC Form 4)

CEO AND PRESIDENT Mohan Raju bought $959,889 worth of shares (500,000 units at $1.92), increasing direct ownership by 30% to 2,175,028 units (SEC Form 4)

$VTYX Leadership Updates

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

$VTYX Financials

Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

$VTYX Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

Recent Analyst Ratings for
$VTYX

Recent Analyst Ratings for
$VTYX

$VTYX
Analyst Ratings

$VTYX
Press Releases

$VTYX
Insider Trading

$VTYX
SEC Filings

$VTYX
Insider Purchases

$VTYX
Leadership Updates

$VTYX
Financials

$VTYX
Large Ownership Changes